AU2010295497B2 - Immunological compositions for HIV - Google Patents

Immunological compositions for HIV Download PDF

Info

Publication number
AU2010295497B2
AU2010295497B2 AU2010295497A AU2010295497A AU2010295497B2 AU 2010295497 B2 AU2010295497 B2 AU 2010295497B2 AU 2010295497 A AU2010295497 A AU 2010295497A AU 2010295497 A AU2010295497 A AU 2010295497A AU 2010295497 B2 AU2010295497 B2 AU 2010295497B2
Authority
AU
Australia
Prior art keywords
hiv
composition
kit
polypeptide
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010295497A
Other languages
English (en)
Other versions
AU2010295497A1 (en
Inventor
Don Francis
Sanjay Gurunathan
Jerome H. Kim
Supachai Rerks-Ngarm
James T. Tartaglia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MINISTRY OF PUBLIC HEALTH
GLOBAL SOLUTIONS FOR INFECTIOUS DISEASES
Sanofi Pasteur Inc
Walter Reed Army Institute of Research
Original Assignee
Mini Of Public Health
GLOBAL SOLUTIONS FOR INFECTIOUS DISEASES
Sanofi Pasteur Inc
Walter Reed Army Institute of Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mini Of Public Health, GLOBAL SOLUTIONS FOR INFECTIOUS DISEASES, Sanofi Pasteur Inc, Walter Reed Army Institute of Research filed Critical Mini Of Public Health
Publication of AU2010295497A1 publication Critical patent/AU2010295497A1/en
Application granted granted Critical
Publication of AU2010295497B2 publication Critical patent/AU2010295497B2/en
Priority to AU2015200094A priority Critical patent/AU2015200094A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2010295497A 2009-09-17 2010-09-17 Immunological compositions for HIV Ceased AU2010295497B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2015200094A AU2015200094A1 (en) 2009-09-17 2015-01-09 Immunological compositions for HIV

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24352209P 2009-09-17 2009-09-17
US61/243,522 2009-09-17
PCT/US2010/049206 WO2011035082A1 (en) 2009-09-17 2010-09-17 Immunological compositions for hiv

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015200094A Division AU2015200094A1 (en) 2009-09-17 2015-01-09 Immunological compositions for HIV

Publications (2)

Publication Number Publication Date
AU2010295497A1 AU2010295497A1 (en) 2012-04-19
AU2010295497B2 true AU2010295497B2 (en) 2014-10-09

Family

ID=43086913

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010295497A Ceased AU2010295497B2 (en) 2009-09-17 2010-09-17 Immunological compositions for HIV

Country Status (6)

Country Link
US (1) US20120308593A1 (enExample)
EP (2) EP2477651A1 (enExample)
JP (3) JP2013505256A (enExample)
AU (1) AU2010295497B2 (enExample)
CA (1) CA2774154A1 (enExample)
WO (1) WO2011035082A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012279018B2 (en) 2011-07-05 2017-06-08 Children's Medical Center Corporation N-terminal deleted GP120 immunogens
CA2850745C (en) 2011-10-03 2022-12-13 Duke University Vaccine
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
CN104968671B (zh) * 2012-09-12 2020-07-03 杜克大学 抗体进化免疫原
WO2014172335A1 (en) 2013-04-15 2014-10-23 Duke University Polyvalent hiv-1 immunogen
US10208358B2 (en) * 2014-04-14 2019-02-19 Indiana University Reasearch and Technology Corporation Generalizable assay for virus capsid assembly
KR20220011685A (ko) 2019-05-22 2022-01-28 길리애드 사이언시즈, 인코포레이티드 Tlr7 조절 화합물과 hiv 백신의 조합
EP4058058A1 (en) 2019-11-14 2022-09-21 Aelix Therapeutics S.L. Dosage regimens for vaccines

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001054701A1 (en) * 2000-01-31 2001-08-02 Aventis Pasteur, S.A. Vaccination of hiv infected persons following highly active antiretroviral therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003531865A (ja) * 2000-04-28 2003-10-28 アメリカ合衆国 Ｄｎａおよびワクシニアウイルスベクターワクチンの組み合わせを用いた免疫原性の改善

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001054701A1 (en) * 2000-01-31 2001-08-02 Aventis Pasteur, S.A. Vaccination of hiv infected persons following highly active antiretroviral therapy

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BELSHE R. B., et al, The Journal of Infectious Diseases, 2001, vol 183, no 9, pages 1343-1352 *
BOGERS W. M. J. M., et al, "Systemic neutralising antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge", Virology, 2008, vol 382, no 2, pages 217-225 *
DOEPEL L. K: "Combination HIV vaccine induces diverse immune responses", NIH news release, 13 July 1999. Retrieved from internet: http://www.nih.gov/news/pr/jul99/niaid-13.htm [retrieved on 4 February 2013] *
GOMEZ-ROMAN V. R., et al, Journal of Acquired Immune Deficiency Syndromes, 2006, vol 43, no 3, pages 270-277 *
GOMEZ-ROMAN V. R., et al, The Journal of Immunology, 2005, vol 174, no 4, pages 2185-2189 *
JOHNSTON M. I., et al, "Progress in HIV vaccine development", Current Opinion in Pharmacology, 2001, vol 1, no 5, pages 504-510 *
PENG B., et al, Journal of Virology, 2005, vol 79, no 16, pages 10200-10209 *
RERKS-NGARM S., et al, "Phase III trial of HIV prime-boost vaccine combination in Thailand: Follow up phase", AIDS research and human retroviruses, 2008, vol 24, supplement 1, page 101 *
RUSSELL N. D., et al, "Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120", Journal of Acquired Immune Deficiency Syndromes, 2007, vol 44, no 2, pages 203-212 *
The AIDS Vaccine Evaluation Group 022 Protocol, The Journal of Infectious Diseases, 2001, vol 183, pages 563-570 *
THONGCHAROEN P., et al, "A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine", Journal of Acquired Immune Deficiency Syndromes, 2007, vol 46, no 1, pages 48-55 *

Also Published As

Publication number Publication date
JP6619788B2 (ja) 2019-12-11
JP2016074727A (ja) 2016-05-12
CA2774154A1 (en) 2011-03-24
WO2011035082A1 (en) 2011-03-24
AU2010295497A1 (en) 2012-04-19
JP2018039832A (ja) 2018-03-15
EP2987500A1 (en) 2016-02-24
EP2477651A1 (en) 2012-07-25
JP2013505256A (ja) 2013-02-14
US20120308593A1 (en) 2012-12-06

Similar Documents

Publication Publication Date Title
JP6619788B2 (ja) Ｈｉｖ用の免疫学的組成物
US20230009041A1 (en) Modified immunization vectors
JP6407714B2 (ja) 短縮型ｈｉｖエンベロープタンパク質（ｅｎｖ）、前記に関連する方法及び組成物
KR102747530B1 (ko) 백신 t 세포 인핸서
US20170065710A1 (en) Immunological Compositions
US11690906B2 (en) Compositions and methods to treat aids
KR20210055725A (ko) 항암 백신을 위한 공유된 종양 항원으로서 herv-k-유래된 항원
CN116322757A (zh) 用于疫苗的剂量方案
CA2846486C (en) Novel clostridium difficile dna vaccine
AU2015200094A1 (en) Immunological compositions for HIV
US20140093556A1 (en) Immunological Compositions Against HIV

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired